-
1
-
-
69149089720
-
-
Lyon, France: International Agency for Research on Cancer (IARC)
-
Stein H, Warnke RA, Chan WC, Jaffe ES, Chan JKC, Gatter KC, et al. editors. Diffuse large B-cell lymphoma, not otherwise specified. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
-
(2008)
Diffuse Large B-cell Lymphoma, Not Otherwise Specified. 4th Ed.
-
-
Stein, H.1
Warnke, R.A.2
Chan, W.C.3
Jaffe, E.S.4
Chan, J.K.C.5
Gatter, K.C.6
-
2
-
-
84864517049
-
Diffuse large B-cell lymphoma: Current strategies and future directions
-
Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 2012;19:204-13.
-
(2012)
Cancer Control
, vol.19
, pp. 204-213
-
-
Cultrera, J.L.1
Dalia, S.M.2
-
3
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
-
(2000)
Nature
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
Ma, C.4
Lossos, I.S.5
Rosenwald, A.6
-
4
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
Fitzgerald, C.4
Gill, K.5
Klasa, R.6
-
5
-
-
84865865930
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study
-
Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26:2103-13.
-
(2012)
Leukemia
, vol.26
, pp. 2103-2113
-
-
Visco, C.1
Li, Y.2
Xu-Monette, Z.Y.3
Miranda, R.N.4
Green, T.M.5
Tzankov, A.6
-
6
-
-
0037443661
-
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3
-
Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003;170:3263-72.
-
(2003)
J Immunol
, vol.170
, pp. 3263-3272
-
-
Niemand, C.1
Nimmesgern, A.2
Haan, S.3
Fischer, P.4
Schaper, F.5
Rossaint, R.6
-
7
-
-
1042302005
-
The STATs of cancer - New molecular targets come of age
-
Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 97-105
-
-
Yu, H.1
Jove, R.2
-
9
-
-
0029117304
-
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
-
Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
-
(1995)
Cell
, vol.82
, pp. 241-250
-
-
Wen, Z.1
Zhong, Z.2
Darnell, J.E.3
-
10
-
-
15744385061
-
Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation
-
Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005;280:11528-34.
-
(2005)
J Biol Chem
, vol.280
, pp. 11528-11534
-
-
Wang, R.1
Cherukuri, P.2
Luo, J.3
-
11
-
-
0033529704
-
Stat3 as an oncogene
-
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
-
(1999)
Cell
, vol.98
, pp. 295-303
-
-
Bromberg, J.F.1
Wrzeszczynska, M.H.2
Devgan, G.3
Zhao, Y.4
Pestell, R.G.5
Albanese, C.6
-
12
-
-
0242285719
-
STAT proteins: From normal control of cellular events to tumorigenesis
-
Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:157-68.
-
(2003)
J Cell Physiol
, vol.197
, pp. 157-168
-
-
Calo, V.1
Migliavacca, M.2
Bazan, V.3
Macaluso, M.4
Buscemi, M.5
Gebbia, N.6
-
13
-
-
33645532055
-
Activation of stat3 in human melanoma promotes brain metastasis
-
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
-
(2006)
Cancer Res
, vol.66
, pp. 3188-3196
-
-
Xie, T.X.1
Huang, F.J.2
Aldape, K.D.3
Kang, S.H.4
Liu, M.5
Gershenwald, J.E.6
-
14
-
-
36849012237
-
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
-
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
-
(2007)
J Clin Invest
, vol.117
, pp. 3846-3856
-
-
Gao, S.P.1
Mark, K.G.2
Leslie, K.3
Pao, W.4
Motoi, N.5
Gerald, W.L.6
-
15
-
-
34548549283
-
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
-
Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007;9:R32.
-
(2007)
Breast Cancer Res
, vol.9
, pp. R32
-
-
Berishaj, M.1
Gao, S.P.2
Ahmed, S.3
Leslie, K.4
Al-Ahmadie, H.5
Gerald, W.L.6
-
16
-
-
84872229121
-
Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer
-
Yang C, Lee H, Jove V, Deng J, Zhang W, Liu X, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS ONE 2013;8:e54029.
-
(2013)
PLoS ONE
, vol.8
, pp. e54029
-
-
Yang, C.1
Lee, H.2
Jove, V.3
Deng, J.4
Zhang, W.5
Liu, X.6
-
17
-
-
82655189564
-
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells
-
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011;71:7226-37.
-
(2011)
Cancer Res
, vol.71
, pp. 7226-7237
-
-
Lin, L.1
Liu, A.2
Peng, Z.3
Lin, H.J.4
Li, P.K.5
Li, C.6
-
18
-
-
7444238184
-
Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines
-
Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004;3:1183-91.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1183-1191
-
-
Barton, B.E.1
Murphy, T.F.2
Shu, P.3
Huang, H.F.4
Meyenhofer, M.5
Barton, A.6
-
19
-
-
84861023172
-
Somatic STAT3 mutations in large granular lymphocytic leukemia
-
Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13.
-
(2012)
N Engl J Med
, vol.366
, pp. 1905-1913
-
-
Koskela, H.L.1
Eldfors, S.2
Ellonen, P.3
Van Adrichem, A.J.4
Kuusanmaki, H.5
Andersson, E.I.6
-
20
-
-
38949165127
-
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
-
Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515-23.
-
(2008)
Blood
, vol.111
, pp. 1515-1523
-
-
Ding, B.B.1
Yu, J.J.2
Yu, R.Y.3
Mendez, L.M.4
Shaknovich, R.5
Zhang, Y.6
-
21
-
-
43549097394
-
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
-
Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008;111:3701-13.
-
(2008)
Blood
, vol.111
, pp. 3701-3713
-
-
Lam, L.T.1
Wright, G.2
Davis, R.E.3
Lenz, G.4
Farinha, P.5
Dang, L.6
-
22
-
-
84872197104
-
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
-
Wu ZL, Song YQ, Shi YF, Zhu J. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011;4:31.
-
(2011)
J Hematol Oncol
, vol.4
, pp. 31
-
-
Wu, Z.L.1
Song, Y.Q.2
Shi, Y.F.3
Zhu, J.4
-
23
-
-
84869786887
-
Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
-
Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 2012;120:4400-6.
-
(2012)
Blood
, vol.120
, pp. 4400-4406
-
-
Gupta, M.1
Maurer, M.J.2
Wellik, L.E.3
Law, M.E.4
Han, J.J.5
Ozsan, N.6
-
24
-
-
84894580544
-
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP
-
Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2013;31:4520-8.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4520-4528
-
-
Huang, X.1
Meng, B.2
Iqbal, J.3
Ding, B.B.4
Perry, A.M.5
Cao, W.6
-
25
-
-
84891606259
-
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program
-
Xu-Monette ZY, Moller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;122:2630-40.
-
(2013)
Blood
, vol.122
, pp. 2630-2640
-
-
Xu-Monette, Z.Y.1
Moller, M.B.2
Tzankov, A.3
Montes-Moreno, S.4
Hu, W.5
Manyam, G.C.6
-
26
-
-
84903789487
-
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
-
Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014;27:958-71.
-
(2014)
Mod Pathol
, vol.27
, pp. 958-971
-
-
Tzankov, A.1
Xu-Monette, Z.Y.2
Gerhard, M.3
Visco, C.4
Dirnhofer, S.5
Gisin, N.6
-
27
-
-
84868602463
-
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study
-
Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120:3986-96.
-
(2012)
Blood
, vol.120
, pp. 3986-3996
-
-
Xu-Monette, Z.Y.1
Wu, L.2
Visco, C.3
Tai, Y.C.4
Tzankov, A.5
Liu, W.M.6
-
28
-
-
0142121516
-
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
-
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
-
(2003)
Biostatistics
, vol.4
, pp. 249-264
-
-
Irizarry, R.A.1
Hobbs, B.2
Collin, F.3
Beazer-Barclay, Y.D.4
Antonellis, K.J.5
Scherf, U.6
-
29
-
-
0037316303
-
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
-
Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
-
(2003)
Bioinformatics
, vol.19
, pp. 185-193
-
-
Bolstad, B.M.1
Irizarry, R.A.2
Astrand, M.3
Speed, T.P.4
-
30
-
-
84879385620
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program
-
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31.
-
(2013)
Blood
, vol.121
, pp. 4021-4031
-
-
Hu, S.1
Xu-Monette, Z.Y.2
Tzankov, A.3
Green, T.4
Wu, L.5
Balasubramanyam, A.6
-
31
-
-
0033521595
-
STAT3 is required for the gp130-mediated full activation of the c-myc gene
-
Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999;189:63-73.
-
(1999)
J Exp Med
, vol.189
, pp. 63-73
-
-
Kiuchi, N.1
Nakajima, K.2
Ichiba, M.3
Fukada, T.4
Narimatsu, M.5
Mizuno, K.6
-
32
-
-
0030292721
-
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in antiapoptosis
-
Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in antiapoptosis. Immunity 1996;5:449-60.
-
(1996)
Immunity
, vol.5
, pp. 449-460
-
-
Fukada, T.1
Hibi, M.2
Yamanaka, Y.3
Takahashi-Tezuka, M.4
Fujitani, Y.5
Yamaguchi, T.6
-
33
-
-
33750036093
-
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
-
Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A 2006;103:15056-61.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 15056-15061
-
-
Joerger, A.C.1
Ang, H.C.2
Fersht, A.R.3
-
34
-
-
77549083560
-
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer
-
Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 11-19
-
-
Grivennikov, S.I.1
Karin, M.2
-
35
-
-
33845865825
-
Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment
-
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 41-51
-
-
Yu, H.1
Kortylewski, M.2
Pardoll, D.3
-
36
-
-
84891909170
-
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
-
Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur C, et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget 2013;4:2430-8.
-
(2013)
Oncotarget
, vol.4
, pp. 2430-2438
-
-
Wu, K.1
Chang, Q.2
Lu, Y.3
Qiu, P.4
Chen, B.5
Thakur, C.6
-
37
-
-
84872227268
-
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer
-
So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, Liu F, et al. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS ONE 2013;8:e54020.
-
(2013)
PLoS ONE
, vol.8
, pp. e54020
-
-
So, J.Y.1
Smolarek, A.K.2
Salerno, D.M.3
Maehr, H.4
Uskokovic, M.5
Liu, F.6
-
38
-
-
80052476422
-
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: Relation to prognosis
-
Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol 2011;28:673-8.
-
(2011)
Med Oncol
, vol.28
, pp. 673-678
-
-
Liu, J.L.1
Wang, X.Y.2
Huang, B.X.3
Zhu, F.4
Zhang, R.G.5
Wu, G.6
-
39
-
-
77649305748
-
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation
-
Stewart DA, Bahlis N, Mansoor A. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2009;50:1276-82.
-
(2009)
Leuk Lymphoma
, vol.50
, pp. 1276-1282
-
-
Stewart, D.A.1
Bahlis, N.2
Mansoor, A.3
-
40
-
-
61349087903
-
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas
-
Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476-87.
-
(2009)
Mod Pathol
, vol.22
, pp. 476-487
-
-
Meier, C.1
Hoeller, S.2
Bourgau, C.3
Hirschmann, P.4
Schwaller, J.5
Went, P.6
-
41
-
-
84884944145
-
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
-
Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013;98:1554-62.
-
(2013)
Haematologica
, vol.98
, pp. 1554-1562
-
-
Valera, A.1
Lopez-Guillermo, A.2
Cardesa-Salzmann, T.3
Climent, F.4
Gonzalez-Barca, E.5
Mercadal, S.6
-
42
-
-
0037474270
-
Opposite regulation of myc and p21waf1 transcription by STAT3 proteins
-
Barre B, Avril S, Coqueret O. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem 2003;278:2990-6.
-
(2003)
J Biol Chem
, vol.278
, pp. 2990-2996
-
-
Barre, B.1
Avril, S.2
Coqueret, O.3
-
43
-
-
0035912763
-
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
-
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001;98:7319-24.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 7319-7324
-
-
Bowman, T.1
Broome, M.A.2
Sinibaldi, D.3
Wharton, W.4
Pledger, W.J.5
Sedivy, J.M.6
-
44
-
-
63249092765
-
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors
-
Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
-
(2009)
Cancer Cell
, vol.15
, pp. 283-293
-
-
Lee, H.1
Herrmann, A.2
Deng, J.H.3
Kujawski, M.4
Niu, G.5
Li, Z.6
-
45
-
-
34249868449
-
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB
-
Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007;21:1396-408.
-
(2007)
Genes Dev
, vol.21
, pp. 1396-1408
-
-
Yang, J.1
Liao, X.2
Agarwal, M.K.3
Barnes, L.4
Auron, P.E.5
Stark, G.R.6
-
46
-
-
84862019471
-
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: Implications for therapy
-
Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2012;26:1356-64.
-
(2012)
Leukemia
, vol.26
, pp. 1356-1364
-
-
Gupta, M.1
Han, J.J.2
Stenson, M.3
Wellik, L.4
Witzig, T.E.5
-
47
-
-
30444431914
-
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation
-
Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006;25:139-49.
-
(2006)
EMBO J
, vol.25
, pp. 139-149
-
-
Williams, S.A.1
Chen, L.F.2
Kwon, H.3
Ruiz-Jarabo, C.M.4
Verdin, E.5
Greene, W.C.6
-
48
-
-
84890606231
-
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
-
Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 2013;19:6882-90.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6882-6890
-
-
Oki, Y.1
Buglio, D.2
Fanale, M.3
Fayad, L.4
Copeland, A.5
Romaguera, J.6
-
49
-
-
79955485953
-
STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma
-
Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011;71:3182-8.
-
(2011)
Cancer Res
, vol.71
, pp. 3182-3188
-
-
Scuto, A.1
Kujawski, M.2
Kowolik, C.3
Krymskaya, L.4
Wang, L.5
Weiss, L.M.6
-
50
-
-
0034284050
-
Prognostic significance of survivin expression in diffuse large B-cell lymphomas
-
Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-5.
-
(2000)
Blood
, vol.96
, pp. 1921-1925
-
-
Adida, C.1
Haioun, C.2
Gaulard, P.3
Lepage, E.4
Morel, P.5
Briere, J.6
|